Progress with Aviva Systems Biology’s Antibody Blast Tool

In an effort to identify antibody candidates for unique or hard-to-find protein targets, Aviva Systems Biology has launched an Antibody Blast tool, which compares sequences submitted by researchers with Aviva’s catalog of over 37,000 polyclonal antibodies.  The unique synthetic peptide antigen, used to produce a corresponding rabbit polyclonal antibody, contains the sequence of interest for this comparison to a researcher’s target-of-interest.

Researchers evaluating unique targets have relatively few commercial options. Most antibody companies have focused on producing reagents for human targets. A few companies offer limited selections of antibodies for common research species, such as: mouse, rat, pig, dog, goat, sheep, rabbit, cow, horse, Zebrafish, and so on.  For researchers focused on species not routinely used by various labs, the options are usually nonexistent.

Many protein domains are conserved among species, leading to a possibility that existing antibodies may work.  Aviva’s objective with the Antibody Blast tool is to evaluate the experimental success rate resulting from predicted sequence homology between a researcher’s submitted sequence and the peptide antigen.  In order to obtain this data, we are seeking collaborations with researchers interested to test antibodies and in return provide Aviva results.

We have been receiving sequences for three months, and can share the following results so far:

  • Aviva’s Antibody Blast was able to find antibody matches ~80% percent of the time a sequence was submitted;
  • When the Antibody Blast found a match, an average of three different antibodies were identified with homology to the protein target;
  • Aviva considers a match to be five consecutive amino acids or greater, or sequence homology of 64% or greater. Of identified matches, 63% were consecutive;
  • The average percent homology of non-consecutive amino acid matches was 70%.

We have intentionally expanded on the homology range for evaluation purposes.  Even if the experimental success rate for each individual antibody is low, an average of three different antibodies per target is expected to increase this success rate considerably.  Experimental results will be the true test of how effective this method is. If successful, Aviva will enable researchers to evaluate more proteins which will lead to new proteomic discoveries.

Aviva Systems Biology provides researchers with an extensive collection of antibodies for research applications, providing solutions over 14,000 unique gene targets.  Aviva is considered to be one of the largest antibody manufacturers due to a systematic production and antibody validation efforts. Key areas of research include transcription factors, epigenetics, cell signaling, membrane proteins, stem cell targets, cancer biomarkers, neuroscience biomarkers, and various cell biology targets.

Interested parties can contact us at

This entry was posted in Blog, News & Announcements and tagged , , , , . Bookmark the permalink.

Leave a Reply